Cleary Gottlieb Steen & Hamilton LLP acted as counsel to the Company, and Sheppard Mullin Richter & Hampton LLP acted as counsel to the underwriters in connection with the offering.​​​​​​​

AnPac Bio-Medical Science Co., Ltd. announced the pricing and trading of its initial public offering.

1,333,360 American depositary shares (“ADSs”) were sold for a total of $16,000,320 in gross proceeds before fees and expenses. AnPac Bio’s ADSs began trading on The Nasdaq Global Market (“Nasdaq”) on Thursday, January 30, 2020 under the trading symbol “ANPC”.

In addition, AnPac Bio has granted the underwriters a 30-day option to purchase up to 200,004 additional ADSs at the initial public offering price less underwriting discounts. If the underwriters choose to exercise their overallotment option, the total capital raised will be approximately $18,460,000.

The underwriters: WestPark Capital, Inc, Univest Securities, LLC, Newbridge Securities Corp, Prime Number Securities, LLC, The Benchmark Company, LLC, WallachBeth Capital, LLC.

The Sheppard Mullin deal team was led by partners Richard Friedman (Picture) and Stephen Cohen, and associates Yuanmei Lu, Nazia Khan, and Matthew Hayes. Partner Jing Liu and associate Paul Chang provided advice on intellectual property matters. Partner Allison Fulton provided advice on FDA matters.

Involved fees earner: Paul Chang – Sheppard Mullin; Stephen Cohen – Sheppard Mullin; Richard Friedman – Sheppard Mullin; Allison Fulton – Sheppard Mullin; Matthew Hayes – Sheppard Mullin; Nazia Khan – Sheppard Mullin; Jing Liu – Sheppard Mullin; Yuanmei Lu – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Newbridge Securities Corp; Prime Number Securities, LLC; The Benchmark Company; Univest Securities, LLC; WallachBeth Capital, LLC; WestPark Capital, Inc.;